DE60329588D1 - Verwendung von epa and dha zur sekundären prevention von schlaganfällen - Google Patents

Verwendung von epa and dha zur sekundären prevention von schlaganfällen

Info

Publication number
DE60329588D1
DE60329588D1 DE60329588T DE60329588T DE60329588D1 DE 60329588 D1 DE60329588 D1 DE 60329588D1 DE 60329588 T DE60329588 T DE 60329588T DE 60329588 T DE60329588 T DE 60329588T DE 60329588 D1 DE60329588 D1 DE 60329588D1
Authority
DE
Germany
Prior art keywords
dha
epa
stroke
secondary prevention
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329588T
Other languages
English (en)
Inventor
Philip Calder
Robert Grimble
Patrick Gallagher
Cliff Shearman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biopharma Norge AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge AS filed Critical Pronova Biopharma Norge AS
Priority claimed from PCT/GB2003/001945 external-priority patent/WO2003092673A1/en
Application granted granted Critical
Publication of DE60329588D1 publication Critical patent/DE60329588D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
DE60329588T 2002-05-03 2003-05-02 Verwendung von epa and dha zur sekundären prevention von schlaganfällen Expired - Lifetime DE60329588D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A GB2388026B (en) 2002-05-03 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes
PCT/GB2003/001945 WO2003092673A1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention

Publications (1)

Publication Number Publication Date
DE60329588D1 true DE60329588D1 (de) 2009-11-19

Family

ID=9936057

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329588T Expired - Lifetime DE60329588D1 (de) 2002-05-03 2003-05-02 Verwendung von epa and dha zur sekundären prevention von schlaganfällen

Country Status (6)

Country Link
JP (1) JP4688203B2 (de)
AT (1) ATE444745T1 (de)
DE (1) DE60329588D1 (de)
ES (1) ES2334656T3 (de)
GB (2) GB0210212D0 (de)
NZ (1) NZ536507A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160989A2 (en) 2013-03-28 2014-10-02 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
US20070149617A1 (en) 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
US7498359B2 (en) 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
KR20110098909A (ko) 2008-11-14 2011-09-02 보미 피. 팜로즈 동맥경화증의 치료를 위한, 순환하는 산화된 저밀도 지방단백질-베타-2-당단백질 1 복합체를 낮추는 방법
CN110538148A (zh) 2009-03-09 2019-12-06 巴斯夫股份公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
EP3263113A1 (de) * 2016-06-30 2018-01-03 Jürgen Mertin Anwendung und präparat (enthaltend colecalciferol, omega-3-fettsäure and ginkgo biloba) zur aufrechterhaltung und verbesserung kognitiver funktionen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
JP2534557B2 (ja) * 1989-03-30 1996-09-18 全国農業協同組合連合会 肉豚用飼料及び食肉用豚の生産方法
JPH05271685A (ja) * 1991-12-26 1993-10-19 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai 高度不飽和脂肪酸含有油脂組成物及び高度不飽和脂肪酸を含有するグリセリド油の製造方法
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
JPH1180083A (ja) * 1997-09-10 1999-03-23 Nof Corp エイコサペンタエン酸エステルの製造方法
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
JP2000159678A (ja) * 1998-11-30 2000-06-13 Nof Corp 皮膚外用剤組成物
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤
CN1250286C (zh) * 2000-05-05 2006-04-12 应用研究系统Ars股份公司 Il－18抑制剂在治疗和/或预防动脉粥样硬化中的应用
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Also Published As

Publication number Publication date
GB0210212D0 (en) 2002-06-12
ATE444745T1 (de) 2009-10-15
GB0307625D0 (en) 2003-05-07
GB2388026A (en) 2003-11-05
ES2334656T3 (es) 2010-03-15
JP4688203B2 (ja) 2011-05-25
NZ536507A (en) 2008-12-24
JP2005529903A (ja) 2005-10-06
GB2388026B (en) 2006-02-08

Similar Documents

Publication Publication Date Title
HK1058883A1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders.
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
BR0309740A (pt) Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
BR9713479A (pt) Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
GB0314624D0 (en) Inflammatory disease treatment
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
PH12014502412A1 (en) Use of dpa (n-6) oils in infant formula
AU7175496A (en) Edible fat-spread
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
EP1992643A3 (de) Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
AU4722801A (en) Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
DK0774962T3 (da) Anvendelse af DHA i behandlingen af ordblindhed
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
WO2008018043A3 (en) Methods of improving bone health and muscle health
ATE444745T1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2843124B1 (fr) Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
NO932984L (no) Fettsyrebehandling
WO2005053669A8 (fr) Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
SE9903915D0 (sv) Kolesterolsänkande och blodfettsänkande komposition
DE69809743D1 (de) An omega-3 ungesättigten fettsäuren angereicherte wachsester, ihre herstellung und verwendung
ATE312604T1 (de) Kombinationspräparat aus omega-3-fettsäuren und konjugierten linolsäuren zur behandlung immunologisch geprägter krankheitsbilder
IL158228A0 (en) Use of esters of long-chain fatty acids for treatment of autoimmune diseases

Legal Events

Date Code Title Description
8363 Opposition against the patent